http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html <ul><li style="text-align:justify;">Virtual corporate presentation available September 11, 2026</li><li style="text-align:justify;">NetraMark management to hold in-person one-on-one investor meetings in New York City September 14th and 15th</li></ul> <p align="justify">TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_CXMhPqN3dtrXVvMh3boUuDUule4ZJW3Kn7dZRlaboZuRHFC0RQ7wbNskeB4tCfgEwLvuDbjfaRwcWIzdxIjwJlz-6mNi6zo23aEdaqhryM=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.</p> <p align="justify">NetraMark Chief Executive Officer George Achilleos will deliver a virtual corporate presentation available beginning September 11, 2026 at http://www.streetinsider.com/Press+Releases/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html Thu, 27 Aug 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html <ul><li style="text-align:justify;">Virtual corporate presentation available September 11, 2026</li><li style="text-align:justify;">NetraMark management to hold in-person one-on-one investor meetings in New York City September 14th and 15th</li></ul> <p align="justify">TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_CXMhPqN3dtrXVvMh3boUuDUule4ZJW3Kn7dZRlaboZuRHFC0RQ7wbNskeB4tCfgEwLvuDbjfaRwcWIzdxIjwJlz-6mNi6zo23aEdaqhryM=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.</p> <p align="justify">NetraMark Chief Executive Officer George Achilleos will deliver a virtual corporate presentation available beginning September 11, 2026 at http://www.streetinsider.com/Press+Releases/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html Thu, 27 Aug 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html <ul><li style="text-align:justify;">Virtual corporate presentation available September 11, 2026</li><li style="text-align:justify;">NetraMark management to hold in-person one-on-one investor meetings in New York City September 14th and 15th</li></ul> <p align="justify">TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_CXMhPqN3dtrXVvMh3boUuDUule4ZJW3Kn7dZRlaboZuRHFC0RQ7wbNskeB4tCfgEwLvuDbjfaRwcWIzdxIjwJlz-6mNi6zo23aEdaqhryM=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.</p> <p align="justify">NetraMark Chief Executive Officer George Achilleos will deliver a virtual corporate presentation available beginning September 11, 2026 at http://www.streetinsider.com/Press+Releases/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html Thu, 27 Aug 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html <ul><li style="text-align:justify;">Virtual corporate presentation available September 11, 2026</li><li style="text-align:justify;">NetraMark management to hold in-person one-on-one investor meetings in New York City September 14th and 15th</li></ul> <p align="justify">TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_CXMhPqN3dtrXVvMh3boUuDUule4ZJW3Kn7dZRlaboZuRHFC0RQ7wbNskeB4tCfgEwLvuDbjfaRwcWIzdxIjwJlz-6mNi6zo23aEdaqhryM=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.</p> <p align="justify">NetraMark Chief Executive Officer George Achilleos will deliver a virtual corporate presentation available beginning September 11, 2026 at http://www.streetinsider.com/Press+Releases/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html Thu, 27 Aug 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html <ul><li style="text-align:justify;">Virtual corporate presentation available September 11, 2026</li><li style="text-align:justify;">NetraMark management to hold in-person one-on-one investor meetings in New York City September 14th and 15th</li></ul> <p align="justify">TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_CXMhPqN3dtrXVvMh3boUuDUule4ZJW3Kn7dZRlaboZuRHFC0RQ7wbNskeB4tCfgEwLvuDbjfaRwcWIzdxIjwJlz-6mNi6zo23aEdaqhryM=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.</p> <p align="justify">NetraMark Chief Executive Officer George Achilleos will deliver a virtual corporate presentation available beginning September 11, 2026 at http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html Thu, 27 Aug 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html <ul><li style="text-align:justify;">Virtual corporate presentation available September 11, 2026</li><li style="text-align:justify;">NetraMark management to hold in-person one-on-one investor meetings in New York City September 14th and 15th</li></ul> <p align="justify">TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_CXMhPqN3dtrXVvMh3boUuDUule4ZJW3Kn7dZRlaboZuRHFC0RQ7wbNskeB4tCfgEwLvuDbjfaRwcWIzdxIjwJlz-6mNi6zo23aEdaqhryM=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.</p> <p align="justify">NetraMark Chief Executive Officer George Achilleos will deliver a virtual corporate presentation available beginning September 11, 2026 at http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html Thu, 27 Aug 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html <ul><li style="text-align:justify;">Virtual corporate presentation available September 11, 2026</li><li style="text-align:justify;">NetraMark management to hold in-person one-on-one investor meetings in New York City September 14th and 15th</li></ul> <p align="justify">TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_CXMhPqN3dtrXVvMh3boUuDUule4ZJW3Kn7dZRlaboZuRHFC0RQ7wbNskeB4tCfgEwLvuDbjfaRwcWIzdxIjwJlz-6mNi6zo23aEdaqhryM=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.</p> <p align="justify">NetraMark Chief Executive Officer George Achilleos will deliver a virtual corporate presentation available beginning September 11, 2026 at http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html Thu, 27 Aug 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html <ul><li style="text-align:justify;">Virtual corporate presentation available September 11, 2026</li><li style="text-align:justify;">NetraMark management to hold in-person one-on-one investor meetings in New York City September 14th and 15th</li></ul> <p align="justify">TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=_CXMhPqN3dtrXVvMh3boUuDUule4ZJW3Kn7dZRlaboZuRHFC0RQ7wbNskeB4tCfgEwLvuDbjfaRwcWIzdxIjwJlz-6mNi6zo23aEdaqhryM=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.</p> <p align="justify">NetraMark Chief Executive Officer George Achilleos will deliver a virtual corporate presentation available beginning September 11, 2026 at http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Participate+in+the+H.C.+Wainwright+28th+Annual+Global+Investment+Conference/26984515.html Thu, 27 Aug 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Press+Releases/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html <p align="justify">TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=U43c4l3rESW4mnQQEIMJl9glvFcLJsYBSO5t7kaWyGlXtyAQ76ko4urw7TnpUhiWq5xltzSCCKdcWVDWLcUVbVcu53piMvw-0a6TsfsykCQ=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.</p> <p align="justify">Over recent months, NetraMark has continued to build across both of its primary commercialization channels: direct engagements with pharmaceutical and biotechnology companies and strategic relationships with contract http://www.streetinsider.com/Globe+Newswire/NetraMark+Corporate+Update+Highlights+Record+C%243.4+Million+in+Fiscal+2026+Contract+Bookings%2C+Up+645%25+from+Previous+Annual+High/26952605.html Thu, 20 Aug 2026 07:00:00 -0400 A.06822034 AIAI AINMF O.20026344 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Engages+AM+Public+Relations+to+Support+Strategic+Communications+and+Market+Awareness/26759534.html <p align="justify">TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hcJAaqu-QKQsHh6Kx2oAfPqQdI_SGIA-JXzBP_lRqDHAg3P5aV1WXY4dUoW8dLVLH0KGSnTqhagdt7lgMCAGXM9czcy0uqUWMLjuLLpUfW0=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced it has engaged <a target="_blank" href="https://www.globenewswire.com/Tracker?data=CCmETSfvdpPdRGIADLiXNcg_2J-QXjf9TA-0xrPbAIvl48nGxJSTMCF1JqX9Ls0s471-KzGj4Yf4W2VgHBbQ6hAqA9vYW9d8jpO11XYqtEU=" rel="nofollow" target="_blank">AM Public Relations</a> (AM PR), a healthcare-focused public relations agency specializing in media relations, thought leadership, and strategic communications for healthcare and technology companies.</p> <p align="justify">The engagement is intended to support NetraMark&apos;s broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry http://www.streetinsider.com/Press+Releases/NetraMark+Engages+AM+Public+Relations+to+Support+Strategic+Communications+and+Market+Awareness/26759534.html Mon, 13 Jul 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Engages+AM+Public+Relations+to+Support+Strategic+Communications+and+Market+Awareness/26759534.html <p align="justify">TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hcJAaqu-QKQsHh6Kx2oAfPqQdI_SGIA-JXzBP_lRqDHAg3P5aV1WXY4dUoW8dLVLH0KGSnTqhagdt7lgMCAGXM9czcy0uqUWMLjuLLpUfW0=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced it has engaged <a target="_blank" href="https://www.globenewswire.com/Tracker?data=CCmETSfvdpPdRGIADLiXNcg_2J-QXjf9TA-0xrPbAIvl48nGxJSTMCF1JqX9Ls0s471-KzGj4Yf4W2VgHBbQ6hAqA9vYW9d8jpO11XYqtEU=" rel="nofollow" target="_blank">AM Public Relations</a> (AM PR), a healthcare-focused public relations agency specializing in media relations, thought leadership, and strategic communications for healthcare and technology companies.</p> <p align="justify">The engagement is intended to support NetraMark&apos;s broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry http://www.streetinsider.com/Press+Releases/NetraMark+Engages+AM+Public+Relations+to+Support+Strategic+Communications+and+Market+Awareness/26759534.html Mon, 13 Jul 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Engages+AM+Public+Relations+to+Support+Strategic+Communications+and+Market+Awareness/26759534.html <p align="justify">TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hcJAaqu-QKQsHh6Kx2oAfPqQdI_SGIA-JXzBP_lRqDHAg3P5aV1WXY4dUoW8dLVLH0KGSnTqhagdt7lgMCAGXM9czcy0uqUWMLjuLLpUfW0=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced it has engaged <a target="_blank" href="https://www.globenewswire.com/Tracker?data=CCmETSfvdpPdRGIADLiXNcg_2J-QXjf9TA-0xrPbAIvl48nGxJSTMCF1JqX9Ls0s471-KzGj4Yf4W2VgHBbQ6hAqA9vYW9d8jpO11XYqtEU=" rel="nofollow" target="_blank">AM Public Relations</a> (AM PR), a healthcare-focused public relations agency specializing in media relations, thought leadership, and strategic communications for healthcare and technology companies.</p> <p align="justify">The engagement is intended to support NetraMark&apos;s broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry http://www.streetinsider.com/Press+Releases/NetraMark+Engages+AM+Public+Relations+to+Support+Strategic+Communications+and+Market+Awareness/26759534.html Mon, 13 Jul 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Engages+AM+Public+Relations+to+Support+Strategic+Communications+and+Market+Awareness/26759534.html <p align="justify">TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hcJAaqu-QKQsHh6Kx2oAfPqQdI_SGIA-JXzBP_lRqDHAg3P5aV1WXY4dUoW8dLVLH0KGSnTqhagdt7lgMCAGXM9czcy0uqUWMLjuLLpUfW0=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced it has engaged <a target="_blank" href="https://www.globenewswire.com/Tracker?data=CCmETSfvdpPdRGIADLiXNcg_2J-QXjf9TA-0xrPbAIvl48nGxJSTMCF1JqX9Ls0s471-KzGj4Yf4W2VgHBbQ6hAqA9vYW9d8jpO11XYqtEU=" rel="nofollow" target="_blank">AM Public Relations</a> (AM PR), a healthcare-focused public relations agency specializing in media relations, thought leadership, and strategic communications for healthcare and technology companies.</p> <p align="justify">The engagement is intended to support NetraMark&apos;s broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry http://www.streetinsider.com/Press+Releases/NetraMark+Engages+AM+Public+Relations+to+Support+Strategic+Communications+and+Market+Awareness/26759534.html Mon, 13 Jul 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Engages+AM+Public+Relations+to+Support+Strategic+Communications+and+Market+Awareness/26759534.html <p align="justify">TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=hcJAaqu-QKQsHh6Kx2oAfPqQdI_SGIA-JXzBP_lRqDHAg3P5aV1WXY4dUoW8dLVLH0KGSnTqhagdt7lgMCAGXM9czcy0uqUWMLjuLLpUfW0=" rel="nofollow" target="_blank">NetraMark Holdings Inc</a>. (the &quot;Company&quot; or &quot;NetraMark&quot;) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced it has engaged <a target="_blank" href="https://www.globenewswire.com/Tracker?data=CCmETSfvdpPdRGIADLiXNcg_2J-QXjf9TA-0xrPbAIvl48nGxJSTMCF1JqX9Ls0s471-KzGj4Yf4W2VgHBbQ6hAqA9vYW9d8jpO11XYqtEU=" rel="nofollow" target="_blank">AM Public Relations</a> (AM PR), a healthcare-focused public relations agency specializing in media relations, thought leadership, and strategic communications for healthcare and technology companies.</p> <p align="justify">The engagement is intended to support NetraMark&apos;s broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry http://www.streetinsider.com/Globe+Newswire/NetraMark+Engages+AM+Public+Relations+to+Support+Strategic+Communications+and+Market+Awareness/26759534.html Mon, 13 Jul 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0